SAN2065

SAN2065 is a small molecule activator of the Kv7 (KCNQ) family of potassium channels, specifically targeting the Kv7.2 and Kv7.3 subunits. Developed by Saniona, the compound is designed to modulate neuronal excitability by facilitating the opening of these channels, which helps stabilize the resting membrane potential and suppress neuronal over-activity. This mechanism is being investigated as a novel approach for treating Major Depressive Disorder (MDD), potentially offering an alternative for patients who do not respond to standard-of-care antidepressants that target monoamine systems. By enhancing the M-current through Kv7.2/7.3 activation, SAN2065 aims to restore normal neuronal firing patterns in brain regions associated with mood regulation.